Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-03-27 00:00:00 ET · period of report 2024-03-25 · accession 0002001011-24-000035 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-03-27 | 2024-03-25 | LGND | Davis Todd C | CEO, Dir | M - OptEx | $57.39 | +16.0K | 120.2K | +15% | +$919.1K |
| DM | 2024-03-27 | 2024-03-25 | LGND | Davis Todd C | CEO, Dir | M - OptEx | $0.00 | -16.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-25 | M | A | 7,448 | $46.20 | 111,593 | D | — | — | |
| 2 | Common | Common Stock | 2024-03-25 | M | A | 2,855 | $67.24 | 114,448 | D | — | — | |
| 3 | Common | Common Stock | 2024-03-25 | M | A | 2,156 | $68.51 | 116,604 | D | — | — | |
| 4 | Common | Common Stock | 2024-03-25 | M | A | 3,556 | $66.19 | 120,160 | D | — | — | |
| 5 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-03-25 | M | D | 3,556 | $0.00 | 0 | D | $66.19 · — to 2029-06-06 | 3,556 Common Stock | (F2) This Option was previously reported as a Grant of 4,071 shares, which vested in full on June 9, 2020, at an exercise price of $113.59 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 6 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-03-25 | M | D | 2,855 | $0.00 | 0 | D | $67.24 · — to 2031-06-04 | 2,855 Common Stock | (F3) This Option was previously reported as a Grant of 3,269 shares, which vested in full on June 4, 2022, at an exercise price of $115.39 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 7 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-03-25 | M | D | 2,156 | $0.00 | 0 | D | $68.51 · — to 2030-06-10 | 2,156 Common Stock | (F4) This Option was previously reported as a Grant of 2,468 shares, which vested in full on June 4, 2021, at an exercise price of $117.58 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| 8 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-03-25 | M | D | 7,448 | $0.00 | 0 | D | $46.20 · — to 2032-06-10 | 7,448 Common Stock | (F1) This Option was previously reported as a Grant of 4,340 shares at an exercise price of $79.29 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer, then vested in full on June 10, 2023. |